Figure 2.
Bispecific antibodies and their target sites in lung cancer therapeutics. Bispecific antibody targets include sites in the tumor cell or an interaction with tumor cell and T-cell. Amivantamab is the only FDA-approved therapy, and other bispecific antibodies are in various stages of clinical trials.
